Africa Live News

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive

africa-live — Tue, 28 Apr 2026 13:03:35 GMT

For Trade and Medical Media Only

The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90
Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs)
Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs)

(BUSINESS WIRE) -- Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT).

The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected.

The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards for fungal-free survival at Day 90, showing non-inferiority of rezafungin vs. SAR (60.7% vs. 59.0%, respectively). This demonstrates that rezafungin’s differentiated pharmacokinetics/pharmacodynamics (PK/PD) profile was comparable to the SAR in reducing the incidence of invasive fungal diseases in a high-risk patient population. Rezafungin was well tolerated, with a safety profile showing a favourable benefit/risk profile for immunocompromised patients.

The Phase III study topline results indicate comparable efficacy against invasive infections from Candida, Aspergillus and Pneumocystis in both therapeutic arms, as well as comparable mortality. In addition, results showed a favourable profile in multiple secondary endpoints, most notably treatment-emergent adverse events leading to dose-reduced interruption or withdrawal of study drug, and treatment-emergent adverse events leading to study discontinuation.

“We are very excited by the study results, which met all its endpoints, and reflect the contribution of patients enrolled across more than 50 centres in seven countries,” said Dr. Yuri Martina, Chief Development & Medical Officer at Mundipharma. “These findings represent a meaningful step forward in advancing care for this vulnerable population. Rezafungin holds the potential to change the standard of care for these patients.”

Mundipharma and its US licensee, CorMedix currently intend to target submission of a supplemental New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results. Mundipharma expects an EMA submission in Q3, 2026.

About rezafungin

Rezafungin is a next-generation echinocandin approved for the treatment of candidaemia and invasive candidiasis in adults.2 Invasive candidiasis continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is as high as 40%.3,4

Rezafungin has been studied for the prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT.

Approximately 1.3 million people worldwide were diagnosed with haematological malignancies in 2019,5 the majority of whom are at risk of treatment‑related neutropenia, leaving them highly vulnerable to invasive fungal infections and underscoring the ongoing unmet need for effective antifungal prophylaxis.

® REZZAYO is a Registered Trademark of Mundipharma, used under licence by Melinta Therapeutics LLC, a wholly owned subsidiary of CorMedix Inc. in the USA.

About Mundipharma

Mundipharma is a global healthcare company with a presence in Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East. In line with its mission, United for Patients, Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease, ophthalmology, oncology, respiratory and central nervous system.

References:

M Quattrone et al. Managing invasive fungal infections during allogeneic hematopoietic transplantation: a 2025 update. Mediterranean Journal of Hematology and Infectious Diseases. 2025;17(1):e2025064. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12422250/ (last accessed April 2026)

REZZAYO® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15479/smpc#gref (last accessed April 2026)

M Bassetti et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care. 2019;23(1):219. Available at: https://pubmed.ncbi.nlm.nih.gov/31200780/ (last accessed April 2026)

A Cortegiani et al. Antifungal agents for preventing fungal infections in non‑neutropenic critically ill patients. The Cochrane Database of Systematic Reviews. 2016;(1):CD004920. Available at: https://pubmed.ncbi.nlm.nih.gov/26772902/ (last accessed April 2026)

N Zhang et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal. 2023:13(1):82. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10188596/pdf/41408_2023_Article_853.pdf (last accessed April 2026)

Job Code: GBL-S-RZF-2600002
Date of preparation: April 2026

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427620065/en/

Permalink
https://www.aetoswire.com/en/news/2704202654576

Contacts
Mundipharma Media Contact:
Liana Del Medico
VP Communications & Corporate Affairs
Mundipharma
media.relations@mundipharma.com

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices

africa-live — Tue, 28 Apr 2026 12:16:55 GMT

KYOTO, Japan - (BUSINESS WIRE) -- Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance　(AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and sleep modes is widely used in battery-powered devices to reduce standby power consumption and extend operating life. In healthcare, applications include capsule endoscopes and medical patches. Wearable devices, including AR glasses and wireless earbuds, as well as security-related IoT devices, such as door open/close detection systems and smart locks, also use this functionality. These devices commonly use silver oxide coin batteries (typically 1.55 V), which impose constraints on both available capacity and operating voltage. AMR sensors used as magnetic switches must therefore minimize current consumption while maintaining stable operation at low voltage. Murata addressed these requirements through a redesign of the AMR sensor’s internal circuitry, enabling ultra-low current consumption and reliable operation down to 1.2 V. This significantly reduces battery consumption during standby operation, supporting device operation for more than two years in typical use. Both devices are housed in a compact package measuring 1.0 × 1.0 × 0.4 mm (0.04 × 0.04 × 0.02 inches), making them suitable for space-constrained designs. The MRMS166R operates over a 1.2 to 3.6 V supply range (1.5 V typ.) with an average current consumption of 20 nA and a maximum current output of 1 mA. The MRMS168R operates over a 2.0 to 3.6 V supply range (3.0 V typ.), with an average current consumption of 80 nA and a maximum output current of 12 mA, providing higher output drive capability for devices requiring increased load current. Murata will continue to expand its AMR sensor lineup and reduce power consumption to support longer operating times and enhanced functionality in medical, wearable, and IoT devices. For more details on the AMR sensor lineup, including MRMS166R and MRMS168R, please visit the product page: [MRMS166R, MRMS168R] For inquiries regarding these products, please Contact US. About Murata Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. View source version on businesswire.com: https://www.businesswire.com/news/home/20260413296947/en/ Permalink https://www.aetoswire.com/en/news/2704202654563 Contacts For more information, please contact: Murata Manufacturing Co., Ltd. Mizuki Matsumoto, prsec_mmc@murata.com Corporate Communications Department

Sun Pharma signs Definitive Agreement to Acquire Organon

africa-live — Tue, 28 Apr 2026 08:29:43 GMT

MUMBAI, India & JERSEY CITY, N.J. - Monday, 27. April 2026 AETOSWire

Organon stockholders to receive US$ 14.00 per share in cash

The deal values Organon at EV of US$ 11.75 billion

Combined Business leverages complementary portfolios and global scale for sustained long‑term value creation

(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimilars, commercialized across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach. Together, Organon’s General Medicines and Women’s Health franchise reflect the company’s commitment to advancing access and affordability for communities around the world.

The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma’s entry into biosimilars as a Top-10 global player. Organon’s portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma’s existing strengths and enhance long‑term value creation.

Upon successful consummation of the transaction, Sun Pharma is poised to be:

Among the top 25 global pharmaceutical companies with combined revenue of US$ 12.4 billion1
A leading player in Established Brands/Branded Generics
A more Innovative Medicines focused company with 27% revenue share
A top 3 company in global Women’s Health, creating a commercial platform for future growth
The 7th Largest global biosimilar player
A company with presence in 150 countries, with 18 large markets, each generating over US$ 100 million revenues
A stronger cash generating company with EBITDA and cash flow set to nearly double, supporting deleveraging from post transaction Net Debt/EBITDA of 2.3x.
The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders.

Dilip Shanghvi, Executive Chairman of Sun Pharma, said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long‑term growth.”

Kirti Ganorkar, Managing Director of Sun Pharma, said, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon’s talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years.”

Carrie Cox, Executive Chair of Organon, commented, “Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions.”

Transaction Summary

Sun Pharma will acquire 100% of Organon’s issued and outstanding shares for cash.
Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks.
The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger.
The transaction is expected to close in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval.
For the year ended 31st December, 2025, Organon reported US$ 6.2 billion in revenue and Adjusted EBITDA of US$ 1.9 billion. Organon had debt of US$ 8.6 billion and cash balance of US$ 574 million. Organon recently closed on a divestiture of a product for which it received an upfront payment of $440 million, the net proceeds of which will further contribute to its March 31, 2026 cash balance.

Advisors & Financing Banks

J.P. Morgan Securities LLC and Jefferies LLC are serving as financial advisors to Sun Pharma.

White & Case LLP is serving as legal advisor and AZB & Partners is serving as legal advisor for India related matters to Sun Pharma.

Citigroup Global Markets Asia Ltd., JPMorgan Chase Bank, N.A. and MUFG Bank, Ltd. are serving as financing banks to Sun Pharma.

Morgan Stanley & Co. LLC is serving as lead financial advisor to Organon, and Goldman Sachs & Co. LLC is serving as financial advisor to Organon. Sullivan & Cromwell LLP is serving as legal advisor to Organon and Cyril Amarchand Mangaldas is serving as legal advisor for India related matters to Organon.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world’s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for about 20% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. “For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).”

About Organon & Co.

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

All statements other than statements of historical facts included in this communication that address activities, events or developments that Organon expects, believes or anticipates will or may occur in the future are forward-looking statements, including, in particular, statements about the expected timing, completion and effects or benefits of the merger. Forward-looking statements may be identified by words such as “will,” “expect,” and “may.” These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond Organon’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: (i) uncertainties as to the timing of the merger; (ii) the risk that the merger may not be completed on the anticipated terms in a timely manner or at all; (iii) the failure to satisfy any of the conditions to the consummation of the merger, including receiving, on a timely basis or otherwise, the minimum vote required by Organon’s stockholders to approve the merger; (iv) the possibility that competing offers or acquisition proposals for Organon will be made; (v) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement, including in circumstances which would require Organon to pay a termination fee; (vii) the effect of the announcement or pendency of the merger on Organon’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (viii) risks related to diverting management’s attention from Organon’s ongoing business operations; (ix) the risk that stockholder litigation in connection with the merger may result in significant costs of defense, indemnification and liability; (x) certain restrictions during the pendency of the merger that may impact Organon’s ability to pursue certain business opportunities or strategic transactions; (xi) the risk that any announcements relating to the merger could have adverse effects on the market price of Organon’s common stock, including if the merger is not consummated; (xii) risks that the benefits of the merger are not realized when and as expected; (xiii) legislative, regulatory and economic developments; and (xiv) other factors discussed in the “Risk Factors” section of Organon’s most recent periodic reports filed with the SEC, including its most recent Annual Report on Form 10-K and subsequent reports filed with the SEC, all of which may be obtained free of charge from the SEC’s website at www.sec.gov. Although Organon believes that the expectations reflected in its forward-looking statements are reasonable, it cannot assure that those expectations will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Organon on its website or otherwise. Organon does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material in respect of the proposed acquisition pursuant to the Agreement and Plan of Merger, dated as of April 26, 2026, by and among Sun Pharma entities and Organon. In connection with the merger, Organon intends to file relevant materials with the SEC, including Organon’s proxy statement in preliminary and definitive form on Schedule 14A (the “Merger Proxy Statement”). Organon will mail the Merger Proxy Statement and a proxy card to its stockholders in connection with the Merger. INVESTORS AND STOCKHOLDERS OF ORGANON ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE MERGER PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT ORGANON, SUN PHARMA AND THE MERGER AND RELATED MATTERS. Investors and stockholders of Organon are or will be able to obtain these documents (when they are available) free of charge from the SEC’s website at www.sec.gov, or through the investor relations section of Organon’s website, https://www.organon.com.

Participants in the Solicitation

Organon and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be “participants” in the solicitation of proxies from stockholders of Organon in favor of the proposed acquisition. Information about Organon’s directors and executive officers is set forth in the 2026 Annual Meeting Proxy Statement, filed with the SEC on April 24, 2026, and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821825/000119312526177411/ogn-20260423.htm>. To the extent holdings of Organon’s securities by its directors or executive officers have changed since the amounts set forth in the 2026 Annual Meeting Proxy Statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=1821825. Additional information concerning the interests of Organon’s participants in the solicitation, which may, in some cases, be different than those of Organon’s stockholders generally, will be set forth in the Merger Proxy Statement when it becomes available. Sun Pharma is not soliciting Organon’s stockholders and is not a participant in Organon’s proxy solicitation.

____________________

1 Basis FY24-25 for Sun Pharma and CY2025 for Organon

View source version on businesswire.com: https://www.businesswire.com/news/home/20260426881370/en/

Permalink
https://www.aetoswire.com/en/news/54522706

Contacts

Sun Pharma:
Investors
Dr. Abhishek Sharma
+91 22 4324 2929
abhi.sharma@sunpharma.com

Media (Global)
Gaurav Chugh
+91 22 4324 5373
gaurav.chugh@sunpharma.com

Media (USA)
Rob Perry
robert.perry@sunpharma.com

Organon:
Investor Relations
Jen Halchak
Jennifer.halchak@organon.com

Media
Kate Vossen
Katherine.vossen@organon.com

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026

africa-live — Tue, 28 Apr 2026 08:24:10 GMT

CONSHOHOCKEN, Pa. - Monday, 27. April 2026 AETOSWire

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI

(BUSINESS WIRE) -- Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes.

Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

“Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we’re bringing together the brightest minds in the industry to show how organizations can harness data to drive real outcomes, from AI to automation to entirely new business models.”

The event will feature visionary keynotes, customer success stories, hands-on learning, and networking opportunities designed to help attendees turn strategy into action.

Featured speakers include:

Venus Williams, Tennis Champion & Entrepreneur

Steve Lucas, Chairman and CEO, Boomi

Ed Macosky, Chief Product and Technology Officer, Boomi

TK Balaji, Chief Information Officer, Post Consumer Brands

John Baker, CIO and CISO, Lexitas

Michael Hanken, SVP of IT, Multiquip Inc.

Prashant Gaonkar, SVP and Global Head Enterprise Integration, Process Orchestration and Supply Chain Management, Cognizant

Ben Schreiner, Head of AI and Modern Data Strategy, AWS

SP Singh, SVP Enterprise Apps and Integration Services, Infosys

William Thomas, AdvisoryX Managing Partner, DXC Technology

Shailesh Ghaisas, Head of Consulting, Enterprise Integration, Tata Consultancy Services (TCS)

Eric Rounds, Vice President of Information Services & Technology, HNL Lab Medicine

And more!

Event Highlights

1. Special Guest Venus Williams
Boomi welcomes Tennis champion and Entrepreneur Venus Williams as its special guest speaker this year!

With 7 Grand Slam titles, 5 Wimbledon championships, and 4 Olympic gold medals, tennis champion Venus Williams is arguably one of the most accomplished and inspiring women in the history of sports. Beginning her rise to the top at the age of 14, Venus quickly took the tennis world by storm—rising to the top-ranked position, breaking countless records, and winning numerous championships.

Off the court, Venus has combined her sharp business acumen with her competitive spirit to build several successful ventures spanning art, design, wellness, and entertainment. She is the founder of V Starr, an award-winning full-service commercial and residential design firm. Venus launched her plant-based protein company, Happy Viking, in December 2020. Additionally, she is an investor and ambassador for the walking and wellness app WeWard, encouraging healthier and more active lifestyles worldwide.

Most recently, Venus partnered with her sister Serena on an exclusive X Originals video podcast series, Stockton Street, which premiered in September 2025. The viral hit series spotlights Venus and Serena as they reflect on their journey to becoming global icons, joined by a dynamic lineup of guests for candid conversations spanning family, health and wellness, mental health, pop culture, entrepreneurship, leadership, ambition, and resilience.

Venus released her health and wellness book, STRIVE, in August 2024 with Amistad and HarperCollins. In it, she draws from her own personal health and wellness journey to share an easy-to-follow yet innovative life improvement program founded on her eight essential tenets: Observe, Appreciate, Balance, Enrich, Soothe, Believe, Inspire, and Strive.

Throughout her career, Venus has been a steadfast advocate for equality. In 2006, UNESCO, the United Nations’ cultural organization, named her its first “Promoter of Gender Equality.” In 2007, it was her unwavering fight that led Wimbledon to award women players the same pay as their male counterparts. In 2023, Venus received the inaugural US Open Billie Jean King Champion of Equality Award, recognizing her continued dedication to promoting equality and leveling the playing field for athletes.

2. Exclusive Announcements
Attendees will be the first to hear Boomi’s latest innovations across the Boomi Enterprise Platform, including advancements in data readiness, workflow automation, and agent management. From breakthroughs that bring data to life to new ways organizations can power AI, analytics, and automation, Boomi World 2026 will showcase what’s next in turning data into action and accelerating business outcomes.

3. Pre-Conference Training and Partner Summit
Starting on May 11, Boomi World will offer optional one- and two-day Pre-Conference Training designed to help attendees build practical expertise across the Boomi Enterprise Platform. These hands-on, instructor-led sessions go beyond individual products to focus on how integration, APIs, data management, and AI agents work together to power real-world, end-to-end solutions.

Attendees can choose from foundational to advanced tracks, including platform-wide learning through Boomi 360, integration-focused courses, and specialized sessions on designing, governing, and powering AI agents with APIs and data — reinforcing how organizations can activate data to drive intelligent automation and scalable outcomes.

Taking place on May 12, the Boomi Partner Summit provides partners with an exclusive look at the future of the Boomi ecosystem. Partners will gain early insight into upcoming innovations, strategic direction, and go-to-market resources designed to help customers activate their data, accelerate AI initiatives, and drive meaningful business transformation.

4. 70+ Breakout Sessions
Boomi World 2026 features five breakout session track groupings along with sessions designed specifically for Higher Education industry attendees and Embedded partners.

Agentic AI: Build a trusted, agentic enterprise.
Attendees will discover how to connect systems, contextualize data, and take control of agentic workflows with Boomi Agentstudio. Sessions span every stage of the journey, from building an initial use case to orchestrating agents across the enterprise.

Integration & Automation: Break down silos with modern integration.
Boomi is the engine for creating compliant and reliable connectivity. Attendees will learn how to move beyond point-to-point integrations with full ecosystem visibility.

Data Management: Deliver trusted data where and when it matters most.
These sessions explore using Boomi’s data management capabilities to break down silos, resolve conflicts, and govern data. Attendees will learn how to transform data from raw inputs into high-quality, trusted data products.

API Management: Govern APIs to activate AI-ready integration.
Boomi API Management delivers unified control to protect systems and data while accelerating modern integration, agentic workflows, and MCP-enabled AI at scale. Attendees will learn how to master API governance and security across a distributed ecosystem.

Platform Orchestration: Activate AI across your business with a unified platform.
Boomi’s unified platform acts as the foundation for organizations to build, govern, and automate across the business. Attendees will discover how Boomi enables AI-driven orchestration through the combined power of integration, data management, API management, AI agents, and more.

5. Networking Opportunities
Connect with technology thought leaders, like-minded professionals, industry experts, and Boomi partners during dedicated networking sessions. Boomi World 2026 provides a unique platform to foster collaboration, share ideas, and build valuable relationships.

Sponsors
A special thanks to Boomi’s partner sponsors for helping make Boomi World 2026 possible, including DXC and Infosys as the Pinnacle sponsors, and AWS, Cognizant, and TCS as Diamond sponsors.

Registration
Registration is open. Secure your spot at Boomi World 2026 by visiting BoomiWorld.com.

To join the Boomi World conversation on social media, use #BoomiWorld.

Additional Resources

Follow Boomi on X, LinkedIn, Facebook, and YouTube

About Boomi
Boomi, the data activation company, brings data to life by integrating and governing it to power everything from AI to BI. The Boomi Enterprise Platform puts data in motion, uniting data readiness, integration and automation, and agent management in one comprehensive solution. Trusted by more than 30,000 customers and supported by a global network of 800+ partners, Boomi is driving agentic transformation — helping organizations of all sizes move faster, operate smarter, and innovate at scale. Discover more at boomi.com.

© 2026 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427600340/en/

Permalink
https://www.aetoswire.com/en/news/2704202654577

Contacts
Media Contact:
Kristen Walker
Global Communications
kristenwalker@boomi.com

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery

africa-live — Tue, 28 Apr 2026 07:27:56 GMT

PHILADELPHIA - As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. (BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. At the core of PCI’s investment plan is a $100 million project at its San Diego campus, featuring a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. Scheduled to be operational in the first half of 2028, the line will more than double the site's existing syringe and cartridge filling capacity. It will be PCI’s second isolator fill-finish line in San Diego, which currently supports and manufactures over 45 FDA-approved products. The campus also hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations and lyophilization for injectables such as nanoparticles, mRNA, mAbs, proteins, and highly potent products. Meanwhile, PCI’s Bedford, New Hampshire campus is commissioning a GMP-ready bespoke isolator vial and lyophilization line that, upon commencing full-scale production this month, will be capable of producing batch sizes of up to 300,000 vials at 400 units per minute, for an annual total of 33 million – among the most robust, state-of-the-art setups of its kind in the US. The campus also will commission a customer-dedicated high-potent sterile fill-finish line slated to be one of a kind in the US. In both San Diego and Bedford, PCI also has invested in cutting-edge automated visual inspection (AVI) systems for sterile fill-finish applications. In total, PCI's US-based AVI infrastructure supports more than 70 million prefilled syringes and cartridges and 40 million vials per year, meeting the exacting standards of global pharmaceutical manufacturers. Investments in Drug-Device Combination Assembly and Packaging Platforms In partnership with leading device manufacturers, PCI has committed to numerous buildouts of autoinjector and drug-device combination assembly infrastructure at its campuses in Philadelphia, PA and Rockford, IL. Coming online via a phased approach over the next six months, the upgrades will significantly increase both capacity and scale, bolstering PCI’s integrated, clinical-through-commercial capabilities. In 2027, PCI will add a third autoinjector line to its existing lineup, bringing its US autoinjector and device assembly capacity to more than 250 million units per year. Featuring multi-device tooling technology and flexible change parts, the company’s autoinjector lines provide comprehensive high-speed assembly, while a dedicated prefilled syringe (PFS) safety device line adds labeling and secondary packaging options. Philadelphia and Rockford also are home to PCI's US Packaging Centers of Excellence, which offer ample capacity for oral solid dose and injectable products, as well as substantial cold chain storage. The GMP-compliant facilities can be rapidly mobilized to support programs at clinical or commercial scale; available capacity across the two sites includes annual accommodation for 40 million blister units, 70 million bottles, and 75 million vials. Pharmaceutical Development Centers of Excellence In conjunction with expanding its manufacturing platform, PCI is investing in dedicated Development Centers of Excellence (CoE) in Bedford, NH and León, Spain. The CoEs will feature development capabilities spanning lyophilization, formulation, analytical support, drug-device combination assets, long-acting injectables and ophthalmic products. They will handle both highly potent and non-potent small molecule and biologic modalities in vial, prefilled syringe and cartridge presentations. The Bedford Development CoE is expected to be operational this May, with León following in June. “The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records to support the development and commercialization of next-generation treatments,” said Salim Haffar, CEO of PCI Pharma Services. “Backed by over $1 billion in global infrastructure investment and decades of operational expertise, PCI’s multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions, toward the evergreen goal of delivering life-changing therapies to patients.” About PCI Pharma Services PCI is a world-leading CDMO providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients. Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit pci.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260427926534/en/ Permalink https://aetoswire.com/en/news/2704202654580 Contacts PCI Pharma Services Christopher Dale, Turchette Agency (973) 227-8080, ext. 116; cdale@turchette.com

tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation

africanewsline — Tue, 28 Apr 2026 06:53:21 GMT

OTTAWA, Ontario - Monday, 27. April 2026 AETOSWire Print Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem (BUSINESS WIRE) -- Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operating model. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and self-adhesive product solutions. Operating across six global regions and serving both complex industrial and fast-moving consumer markets, tesa continues to expand its portfolio and geographic footprint. As growth increased complexity across functions, regions, and business units, the company identified the need for a scalable, integrated planning foundation that enables faster and more confident decisions across the enterprise. “tesa is operating at a higher level of global scale and complexity than ever before,” said Andreas Rummert, Head of Global Operations at tesa SE. “Our ambition is to establish integrated business planning as a core enterprise capability that enables faster, more confident decision making and helps us respond quickly to changing market and customer needs. To support our growth and innovation agenda, we needed a platform with global visibility, speed and strong scenario capabilities. Kinaxis Maestro, with its powerful orchestration capabilities, was the clear choice to support this ambition.” From a technology perspective, collaboration, integration, and future readiness were critical selection criteria. “Choosing Kinaxis as our strategic partner accelerates tesa’s AI strategy by embedding advanced analytics and AI-driven decision support directly into our core planning processes,” said Christoph Hummel, Head of DIT at tesa SE. “At the same time, we retain clear ownership of our planning model, decision logic and governance. From a technology perspective, this transformation modernizes our planning architecture and strengthens collaboration between Supply Chain and Digital & IT to sustainably build analytics and AI-enabled planning capabilities across the enterprise.” Kinaxis Maestro was selected for its ability to manage real‑world complexity at scale while delivering fast time‑to‑value with lower transformation risk. The platform unifies demand, supply, inventory and sales and operations planning (S&OP) in a single environment, enabling concurrent scenario evaluation and confident decision‑making in real time. “tesa had highly complex requirements,” said Fabienne Cetre, EVP EMEA Sales at Kinaxis. “With Maestro, we can support tesa in building a globally consistent and scalable supply chain planning backbone that helps the organization respond faster while building a strong foundation for the future. This collaboration reflects Kinaxis’ continued momentum in Europe, particularly within specialty materials and advanced manufacturing, with Maestro selected for its industry-leading ability to support the most complex organizational transformations.” To learn more visit kinaxis.com. About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn. Source: Kinaxis Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20260427326206/en/ Permalink https://www.aetoswire.com/en/news/2704202654573 Contacts Media Relations Erin Boyle | Kinaxis eboyle@kinaxis.com +1 519-574-4065 Investor Relations Rick Wadsworth | Kinaxis rwadsworth@kinaxis.com 613-907-7613

SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer

africa-live — Tue, 28 Apr 2026 06:05:28 GMT

Thales adopts SAP RISE private cloud edition on S3NS to transform its ERP (Enterprise Resource Planning) landscape and operationalize digital sovereignty at scale. By combining SAP’s enterprise applications and Business AI capabilities with S3NS’s trusted infrastructure, this partnership unlocks cloud adoption for highly regulated sectors, including public administration, aerospace and defense, and operators of vital and essential services. (BUSINESS WIRE)--Thales (Euronext Paris: HO): A decisive step in scaling trusted cloud in Europe The strategic partnership between SAP and S3NS, the trusted cloud provider established by Thales and Google Cloud, will strengthen trusted cloud capabilities in France and support Europe’s growing demand for cloud business transformation. SAP RISE private cloud edition will be deployed by SAP Sovereign Cloud on S3NS’ SecNumCloud-qualified Cloud Platform, known as PREMI3NS, by H2 2026 enabling organizations to run critical workloads in a trusted environment aligned with French and European regulations. Data will remain stored, processed, and encrypted in France under French jurisdiction, while benefiting from the best cloud technology and SAP’s full innovation stack, including AI-driven capabilities. “This partnership represents a major step forward for our customers in France and sends a strong signal across Europe. Customers can combine SAP’s innovation and scalability within an environment that meets the highest regulatory requirements, enabling transformation without compromise,” said Thomas Saueressig, Chief Customer Officer and Member of the Executive Board of SAP SE. Thales leads the way as first SAP customer on S3NS’ SecNumCloud infrastructure As first SAP customer within the S3NS trusted cloud, Thales is undertaking a transformational refoundation of its SAP ERP landscape, adopting SAP's 'clean core' principle to ensure long-term agility and future-readiness. This program will unify core business processes, including finance, supply chain, manufacturing and procurement, on PREMI3NS, the Trusted Cloud by S3NS. “SAP is a cornerstone of Thales’ transformation, with a proven track record in supporting complex industrial operations and supply chain environments. Leveraging SAP within a trusted cloud platform such as PREMI3NS by S3NS is a natural step in our transformation journey, delivering the security, resilience, and compliance the Group requires,” said Pascal Bouchiat, Senior Executive Vice-President, Chief Financial Officer, Thales. S3NS expands its ecosystem of software partners with SAP SAP selects S3NS to expand its cloud ecosystem in France, leveraging S3NS’s SecNumCloud-aligned infrastructure, which is designed to address requirements related to the protection of sensitive data against extraterritorial laws, with the offering expected to be commercially available and deployed by H2 2026. “France is leading the way in shaping digital sovereignty in Europe, and SecNumCloud sets a clear benchmark for a trusted cloud environment. Together with S3NS, we are enabling customers to move their most critical workloads to the cloud under French jurisdiction - combining sovereignty and innovation in one consistent model. Thales, a global tech leader in defence, aerospace, cyber and digital, choosing this setup is a strong signal that sovereign cloud is becoming a reality at scale,” said Martin Merz, President SAP Sovereign Cloud. “Having a partner as demanding as SAP choosing S3NS is a strong endorsement of our trajectory and the continuous enrichment of our trusted cloud offering. This collaboration marks an important step in expanding our ecosystem of leading software publishers, while accelerating our development. It also enables regulated sectors in France to fully benefit from SAP’s capabilities in a trusted cloud environment. Customers can now access the same level of performance, innovation, and functionality — with the added guarantees of security, compliance, and digital sovereignty provided by S3NS,” said Hélène Bringer, President of S3NS. S3NS already serves more than sixty customers and offers the broadest range of services on the market: 30 managed services with 30 more planned over the next 12 months, including Vertex AI services that facilitate AI adoption. A strong signal to the market and regulated industries Large enterprises and public sector organizations can now accelerate their cloud and AI transformation without regulatory trade-offs Trusted cloud becomes a scalable, industrialized reality, not a niche or constrained option The partnership is not only an intent, but a strong commitment from SAP and S3NS, with a clear and short-term delivery roadmap for availability About SAP As a global leader in enterprise applications and business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit: www.sap.com. About S3NS An alliance between Thales, a global leader in data protection and cybersecurity, and Google Cloud, one of the world’s leading cloud technology providers, S3NS offers public institutions and private companies—seeking to further protect their most sensitive data—highly secure public cloud solutions to support their transition to a trusted cloud, in compliance with the SecNumCloud framework defined by ANSSI, the French National Agency for the Security of Information Systems. S3NS is a company incorporated under French law and wholly controlled by Thales. About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion. The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion. PLEASE VISIT Thales Group S3NS | Thales x Google Cloud visant le cloud de confiance s3ns.io/ecosysteme Recent images of Thales and its Defence, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team. View source version on businesswire.com: https://www.businesswire.com/news/home/20260426644177/en/ Permalink https://aetoswire.com/en/news/54522566 Contacts Thales, Media relations Marion Bonnet Marion.bonnet@thalesgroup.com +33 6 60 38 48 92 SAP Press Contact Sylvie LECHEVIN | sylvie.lechevin@sap.com | 06 28 74 99 23

70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI

africa-live — Tue, 28 Apr 2026 05:47:26 GMT

Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments (BUSINESS WIRE) -- AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operating beyond IT oversight. At the same time, 80% expect to increase their reliance on AI within the next year. “AI adoption is no longer the challenge. Execution is,” said Rakshit Ghura, Vice President and General Manager, Digital Workplace Solutions, Lenovo. “Usage is growing faster than organizations can control or secure it. Without that control, AI introduces as much risk and cost as it does opportunity.” Uncontrolled AI is Already Impacting Business Performance When AI usage scales without visibility or governance, the impact is not theoretical. It is already affecting cost, security posture, and the ability to scale AI across the business. Organizations are experiencing: Delayed ROI, as AI initiatives remain fragmented across teams Duplicated spend, with multiple tools solving the same problems in silos Increased attack surface, as unsanctioned tools access enterprise data Lack of visibility, making it difficult to scale what works At the same time, AI adoption is uneven across the workforce. While some employees operate within secure, optimized environments, others rely on whatever tools they can access to stay productive. This creates a two speed workforce that slows decision making, duplicates effort, and makes consistent, enterprise wide AI adoption difficult to achieve. Uncontrolled AI Is Expanding Your Attack Surface Faster Than Security Can Respond As AI usage accelerates, risk is scaling with it. 61% of IT leaders report a rise in cybersecurity threats linked to AI, yet only 31% feel confident in their ability to manage those risks. Meanwhile, 43% of employees are worried about AI-driven data exposure or attacks. Without clear governance, AI is quietly expanding the enterprise attack surface, increasing the likelihood of breaches, compliance failures, and operational disruption. The Problem: AI Is Being Managed in Fragments Most organizations are trying to manage AI across disconnected layers. Devices are deployed and managed one way. Infrastructure is managed another. Security is often layered on after. That fragmentation is what creates the AI execution gap. Adding more tools or policies does not solve the problem. It increases complexity, leaves gaps between endpoints and infrastructure, and makes it difficult to enforce consistent control across the environment. Lenovo’s Approach: Control AI at the Device and Operate Security as a Service Lenovo takes a fundamentally different approach. Control is established at the point where AI first enters the enterprise: the device. From there, Lenovo connects device deployment, lifecycle management, infrastructure, and security into a single, governed operating model delivered through TruScale Device as a Service for Security. This is not just a combination of technology. It is a fully managed service that brings together: Enterprise grade devices, secured from day one Built in device and firmware protection through Lenovo ThinkShield Advanced endpoint security from leading partners 24/7 managed security services, including monitoring, detection, and response Most organizations have to assemble and operate this themselves across multiple vendors. Lenovo delivers it as a single, end to end managed service, reducing complexity and closing gaps across the environment. Because security is embedded at deployment and actively managed over time, organizations can: Reduce risk with proactive, always on threat monitoring and response Eliminate gaps between device security and operational security Simplify vendor management and lower total cost of ownership Free up internal IT and security teams to focus on higher value initiatives This is what sets Lenovo apart. Instead of managing devices, infrastructure, and security separately, Lenovo applies one continuous control model across the entire environment, something other vendors cannot deliver in a single offering. Delivered through a flexible, as a service model, this approach allows you to align AI investment with actual demand, reducing upfront costs, avoiding duplicated spend, and scaling devices and security services as AI adoption evolves. Lenovo’s approach to cybersecurity and device protection has also been recognized externally, most recently through the Fortress Cybersecurity Awards. Close the AI Execution Gap, and Start Realizing ROI Faster More than 70% of employees already recognize AI's potential to drive gains in productivity, speed, and quality. However realizing that value depends on execution. Organizations that close the AI execution gap can move from fragmented experimentation to measurable outcomes faster. They reduce wasted spend, limit risk, and create a clear path to scaling AI across the business. When devices, infrastructure, and services operate under a unified, managed model, AI shifts from an unmanaged liability to a controlled, scalable advantage. To explore the full findings, download the complete Work Reborn Report: Leading your Workforce to Triumph with AI. About Lenovo Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. Notes for editors Leading your Workforce to Triumph with AI is the fifth report in the Lenovo Work Reborn Research Series. Previous Work Reborn reports examined AI transformation from the IT leader perspective; this report focuses on the employee. Lenovo surveyed 6,000 full-time employees at enterprise organizations (1,000 employees plus), in December 2025 and January 2026. The survey sample included respondents from the US (17%), Canada, UK, France, Germany, India, Japan, Singapore, Brazil, Mexico (8% each), Australia (4%), and New Zealand (4%). Respondents included employees from a range of sectors, a mix of functions and seniority, and with an even spread of ages and genders. Lenovo is a trademark of Lenovo. All other trademarks are the property of their respective owners. ©2026 Lenovo Group Limited. All rights reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260427718577/en/ Permalink https://aetoswire.com/en/news/2704202654569 Contacts Zeno Group for Lenovo: lenovossg@zenogroup.com

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

africa-live — Mon, 27 Apr 2026 07:12:40 GMT

VIENNA - Saturday, 25. April 2026

(BUSINESS WIRE) -- Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages.

Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.”

The Product in Dispute

The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory.

First Arbitration and Set-aside Proceedings

Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety.

Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded.

Second Arbitration

In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made.

Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position

In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard.

On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible.

AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on.

About BESREMi®

BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies.

BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen.

For the EMA Summary of Product Characteristics please visit: BESREMi®

About AOP Health

AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine.

At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners.

With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions.

1 https://www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/

2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260424005227/en/

Permalink
https://www.aetoswire.com/en/news/2504202654551

Contacts
Further inquiry
Nina Roth
Nina.Roth@aop-health.com
+43-676-3131509

SLB Announces First-Quarter 2026 Results

africa-live — Mon, 27 Apr 2026 06:41:51 GMT

HOUSTON -
SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global presence in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Conference Call Information

SLB will hold a conference call to discuss the earnings press release and business outlook on Friday, April 24, 2026. The call is scheduled to begin at 11:00 a.m. U.S. Eastern time. To access the call, which is open to the public, please contact the conference call operator at +1 (833) 470-1428 within North America, or +1 (404) 975-4839 outside of North America, approximately 10 minutes prior to the call’s scheduled start time, and provide the access code 742955. At the conclusion of the conference call, an audio replay will be available until May 1, 2026, by dialling +1 (866) 813-9403 within North America, or +1 (929) 458-6194 outside of North America, and providing the access code 360731. The conference call will be webcasted simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. A replay of the webcast will also be available at the same website until May 1, 2026.

Forward-Looking Statements

This first-quarter 2026 earnings press release, as well as other statements we make, contain “forward-looking statements” within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as “expect,” “may,” “can,” “believe,” “predict,” “plan,” “potential,” “projected,” “projections,” “precursor,” “forecast,” “outlook,” “expectations,” “estimate,” “intend,” “anticipate,” “ambition,” “goal,” “target,” “scheduled,” “think,” “should,” “could,” “would,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements about our financial and performance targets and other forecasts or expectations regarding, or dependent on, our business outlook; growth for SLB as a whole and for each of its Divisions (and for specified business lines, geographic areas, or technologies within each Division); the benefits of the ChampionX acquisition, including the ability of SLB to integrate the ChampionX business successfully and to achieve anticipated synergies and value creation from the acquisition; oil and natural gas demand and production growth; oil and natural gas prices; forecasts or expectations regarding energy transition and global climate change; improvements in operating procedures and technology; capital expenditures by SLB and the oil and gas industry; our business strategies, including digital and “fit for basin,” as well as the strategies of our customers; our capital allocation plans, including dividend plans and share repurchase programs; our APS projects, joint ventures, and other alliances; the impact of the ongoing or escalating conflicts on global energy supply; access to raw materials; future global economic and geopolitical conditions; future liquidity, including free cash flow; and future results of operations, such as margin levels. These statements are subject to risks and uncertainties, including, but not limited to, changing global economic and geopolitical conditions; changes in exploration and production spending by our customers, and changes in the level of oil and natural gas exploration and development; the results of operations and financial condition of our customers and suppliers; the inability to achieve our financial and performance targets and other forecasts and expectations; the inability to achieve our net-zero carbon emissions goals or interim emissions reduction goals; general economic, geopolitical, and business conditions in key regions of the world; foreign currency risk; inflation; changes in monetary policy by governments; tariffs; pricing pressure; weather and seasonal factors; unfavorable effects of health pandemics; availability and cost of raw materials; operational modifications, delays, or cancellations; challenges in our supply chain; production declines; the extent of future charges; the inability to recognize efficiencies and other intended benefits from our business strategies and initiatives, such as digital or new energy, as well as our cost reduction strategies; changes in government regulations and regulatory requirements, including those related to offshore oil and gas exploration, radioactive sources, explosives, chemicals, and climate-related initiatives; the inability of technology to meet new challenges in exploration; the competitiveness of alternative energy sources or product substitutes; and other risks and uncertainties detailed in this press release and our most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the Securities and Exchange Commission (the “SEC”).

If one or more of these or other risks or uncertainties materialize (or the consequences of any such development changes), or should our underlying assumptions prove incorrect, actual results or outcomes may vary materially from those reflected in our forward-looking statements. Forward-looking and other statements in this press release regarding our environmental, social, and other sustainability plans and goals are not an indication that these statements are necessarily material to investors or required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking environmental, social, and sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. Statements in this press release are made as of the date of this release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422463846/en/

Permalink
https://aetoswire.com/en/news/2404202654545

Contacts
Investors
James R. McDonald — SVP, Investor Relations & Industry Affairs, SLB
Joy V. Domingo — Director of Investor Relations, SLB
Tel: +1 (713) 375-3535
investor-relations@slb.com

Media
Josh Byerly — SVP of Global Communications, SLB
Moira Duff — Director of External Communications, SLB
Tel: +1 (713) 375-3407
media@slb.com